Indian Army Amorphous Hydrogel Wound Dressing & Pharmaceutical Tablets Tender SENAPATI Manipur 2025

Tender Overview

The opportunity is issued by the Indian Army (Department Of Military Affairs) for a diversified medical procurement package located in SENAPATI, MANIPUR 795007, covering an Amorphous Hydrogel Wound Dressing with colloid gel 50gm, multiple pharmaceutical tablets including Fenofibrate 160 mg, Etizolam 0.5 mg, Escitalopram 5 mg, Clonazepam 0.5 mg, Brivaracetam 100 mg, Desvenlafaxine 50 mg, Diclofenac 50 mg, Serratiopeptidase 10 mg, Bisoprolol 2.5 mg, Acarbose 25 mg, Febuxostat 80 mg, Rutoside 200 mg, Trypsin 96 mg, Bromelin 180 mg, Alfuzosin 10 mg, Cyclosporine 50 mg/25 mg and other listed components with Calcium, Magnesium, Zinc, Methylcobalamin, and related vitamins. The package comprises 18 BOQ items with an estimated value not disclosed and requires EMD documentation, turnover verification, OEM turnover criteria, and a warranty/service SLA. The tender emphasizes delivery flexibility via option clauses and a need for timely service personnel during warranty.

The procurement context focuses on compliance with medical-grade product categories, supplier qualifications, and delivery terms aligned with government procurement norms. A key differentiator is the OEM turnover criterion and post-award service commitments, with warranty and SLA expectations outlined in the bid terms. Unique aspects include extensive pharmacological range and wearable wound dressing SKU mix within a single contract context.

Keywords to guide bidders include tender in SENAPATI, Manipur; Indian Army procurement; ISI/ISO standards if referenced; and OEM turnover compliance.

Technical Specifications & Requirements

• No explicit technical specifications published in the tender data; itemized BOQ items exist (18 total) but exact quantities and units are not disclosed.
• Provided product categories span wound dressing and a broad spectrum of prescription medicines, some with dosages such as Fenofibrate 160 mg, Etizolam 0.5 mg, Escitalopram 5 mg/20 mg, Diclofenac 50 mg, Febuxostat 80 mg, Brivaracetam 100 mg, and Cyclosporine 50 mg/25 mg.
• EMD (Earnest Money Deposit) amount is not disclosed in the data; bidders must check bid document for precise value.
• Turnover criteria exist for bidders and OEMs, requiring three-year average annual turnover data; turnover evidence must be certified by auditors or CA/Cost Accountant.
• Warranty and post-sales service requirements specify deployment of dedicated technical personnel for timely servicing under a Service Level Agreement; SLA terms not numerically specified here.
• Optional quantity expansion up to 25% during and after contract execution, with delivery time recalculation per the formula provided in terms.
• Delivery timelines anchor from the last date of the original delivery order; extended delivery time follows the option clause with minimum 30 days, subject to constraints.
• No explicit standard numbers (IS/ISO) published in the data; bidders should verify any required certifications in the official tender documents.

Terms, Conditions & Eligibility

• Option Clause: Purchaser may increase/decrease quantity by up to 25% at contract; extended delivery time calculations apply with minimum 30 days.
• Turnover: Minimum average annual turnover over the last 3 years must be demonstrated via audited statements or CA/Cost Accountant certificate; OEM turnover criteria apply for the offered product category.
• OEM Turnover: OEM must meet minimum average turnover criteria; in bunch bids, OEM of the highest bid value category must satisfy this criterion.
• Warranty/Service: Dedicated technical personnel to attend service requests within time, with SLA-based warranty servicing obligations.
• Documentation: Required bid documents include GST, PAN, experience certificates, financial statements, EMD documentation, and OEM authorizations where applicable; submit with bid as per terms.
• All terms align with standard government procurement norms and the contract will incorporate the above conditions.